The FDA label update boosts GE HealthCare’s Vizamyl to a market advantage despite the emergence of blood-based tests.

GE HealthCare Technologies Inc. GEHC has received the FDA’s approval for an updated label for its positron emission ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

The revised label expands the brain-scan agent's use, and means that Vizamyl can now be used to diagnose Alzheimer's and predict the development of dementia due to disease, the company said. The ...

GE HealthCare (GEHC) announced that the U.S. Food and Drug Administration has approved an updated label for its positron emission tomography or PET imaging agent Vizamyl (flutemetamol F 18 injection) ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects ... Similar concerns have also been raised with rival anti-amyloid ...

Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

Insulin resistance detected by routine triglyceride-glucose (TyG) index can flag people with early Alzheimer's who are four ...

June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.

A simple blood test could reveal which early Alzheimer’s patients are most at risk for rapid decline. Researchers found that ...

We were surprised to see the effect only in the Alzheimer’s spectrum and not in other neurodegenerative diseases." The post ...

Research reveals that a blood test measuring insulin resistance via the TyG index may identify individuals with early ...